

Leberzirrhose: Prozess mit Pro- und Regressionspotential

Cirrhose hépatique: potentiel de progression et régression

Literatur / Références

- 1 Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. *Hepatology*. 2010;51(4):1445–9.
- 2 Friedman SL, Bansal MB. Reversal of hepatic fibrosis – fact or fantasy? *Hepatology*. 2006;43(2 Suppl 1):S82–8.
- 3 Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet*. 2013;381(9865):468–75.
- 4 Hytioglou P, Snover DC, Alves V, Balabaud C, Bhathal PS, Bioulac-Sage P, et al. Beyond “cirrhosis”: a proposal from the International Liver Pathology Study Group. *Am J Clin Pathol*. 2012;137(1):5–9.
- 5 Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. *J Hepatol*. 2013;58(3):593–608.
- 6 Rosselli M, MacNaughtan J, Jalan R, Pinzani M. Beyond scoring: a modern interpretation of disease progression in chronic liver disease. *Gut*. 2013;62(9):1234–41.
- 7 Fleming KM, Aithal GP, Card TR, West J. The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. *Aliment Pharmacol Ther*. 2010;32(11–12):1343–50.
- 8 Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology*. 2005;128(2):343–50.
- 9 D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *J Hepatol*. 2006;44(1):217–31.
- 10 Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. *J Hepatol*. 2005;42 (Suppl.1):S100–7.
- 11 Mueller S, Sandrin L. Liver stiffness: a novel parameter for the diagnosis of liver disease. *Hepat Med*. 2010;2:49–67.
- 12 Berzigotti A, Seijo S, Arena U, Abraldes JG, Vizzutti F, Garcia-Pagan JC, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. *Gastroenterology*. 2013;144(1):102–11 e1.
- 13 O’Brien J, Triantos C, Burroughs AK. Management of varices in patients with cirrhosis. *Nat Rev Gastroenterol Hepatol*. 2013;10(7):402–12.
- 14 EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol*. 2012;56(4):908–43.
- 15 Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. *PLoS Med*. 2014;11(4):e1001624.
- 16 Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, Pinter M, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. *Gut*. 2013;62(11):1634–41.